We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Biomarker Identified for Multiple Myeloma

By LabMedica International staff writers
Posted on 02 Jan 2013
A molecule that typically prevents cell death has been identified as a potential biomarker to identify an incurable form of cancer in the bone marrow. More...


Most people who develop this cancer, known as multiple myeloma (MM), have no clearly identifiable risk factors for the disease except for being older than 50 years of age, male and obese, which may predispose individuals to the cancer.

Scientists at the Agency for Science, Technology and Research (A*STAR, Singapore) discovered that a protein called Fas apoptosis inhibitory molecule (FAIM) can affect the activation of alpha serine/threonine-protein kinase (AKT), an important enzyme required for cancer cell proliferation. The team used various techniques including cell culture, Western blot analysis of protein expression, transfection, and cell viability assays.

They also investigated the messenger ribonucleic acid (mRNA) expression of FAIM in normal and malignant plasma cell samples from 15 healthy individuals and 147 patients with various plasma cell neoplasms. The latter include 22 cases of monoclonal gammopathy of undetermined significance, 24 smoldering MM and 101 symptomatic MM and of the 101MM cases, 72 were newly diagnosed, and 29 were relapsed cases. The FAIM expression level was found to be significantly increased in MM patients compared with normal individuals. More importantly, when compared with asymptomatic but malignant condition such as smoldering MM, the expression level of FAIM was again found to be higher for MM. Therefore, FAIM appears to be aberrantly upregulated in MM.

Lam Kong-Peng, PhD, the professor who led the study said, "We found that this protein was present at higher levels in the plasma cells of these patients as compared to normal individuals, and that higher levels of FAIM correlated to poorer survival outcomes of patients. This is an important breakthrough as it not only identifies FAIM as a useful biomarker of multiple myeloma patients, but also as a good target that drugs can be developed for, in order to get rid of the cancer cells." The study was published on December 4, 2012, in the journal Leukemia.

Related Links:

Singapore Agency for Science, Technology and Research 



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Silver Member
Connectivity Solution
EKF Link
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The test combines RNA signals from the tumor-immune microenvironment to predict treatment response, rather than relying on a single marker such as PD-L1 expression.(Image Credit: Adobe Stock)

RNA-Based Test Predicts Immunotherapy Response in Non-Small Cell Lung Cancer

Non-small cell lung cancer (NSCLC) represents the largest U.S. patient population eligible for immune checkpoint inhibitor therapy. Treatment selection often relies on PD-L1 expression, but a single protein... Read more

Immunology

view channel
Image Credit: Adobe Stock

Immune Profiling Identifies Early Maternal Autoantibodies Linked to Preterm Birth Risk

A typical pregnancy lasts about 40 weeks, but labor begins prematurely in roughly one in 10 pregnancies. Preterm birth is the leading cause of newborn death worldwide, yet its underlying causes and which... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: NeoGenomics selected Indica Labs’ HALO AP platform to eable its digital pathology operations through a scalable, cloud-based framework (Photo courtesy of Indica Labs)

Expanded Partnership Scales AI-Powered Digital Pathology for Oncology

Oncology diagnostics rely on pathology and biomarker information to guide personalized treatment. As computational pathology and artificial intelligence (AI) expand insights from tissue analysis, laboratories... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.